Biopure Submits Hemopure Application In The U.K.
This article was originally published in The Pink Sheet Daily
The company says it targeted the United Kingdom before the rest of the EU because of the country's "unique blood banking issues."
You may also be interested in...
The day before Biopure's July 14 review, FDA's Blood Products Advisory Committee will discuss Nabi's Nabi-HB immunoglobulin for hepatitis B.
The company has established a cardiology medical advisory board under the direction of new CEO Zafiris Zafirelis. Biopure expects that data from FDA-requested animal studies will allow it to move forward with U.S. clinical trials for cardiac ischemia.
Singapore-based institute is also looking at dengue fever and malaria, exec says in interview with “The Pink Sheet” DAILY.